Skip to main content

Alecnib 150 mg ( Alectinib)

Introduction to Alectinib Clinical Information

Alecnib 150 mg is identified as a product containing alectinib, a targeted anticancer medicine belonging to the anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor class.

Alectinib is used in specified patients with ALK-positive non-small cell lung cancer (NSCLC). Its clinical role is based on the presence of an abnormal molecular alteration involving the ALK gene, which can contribute to cancer-cell growth and survival.

Unlike treatments selected solely according to the location or appearance of a tumor, alectinib treatment requires consideration of the cancer’s molecular characteristics. Appropriate diagnostic testing is therefore essential before an ALK inhibitor is selected.

This page provides an overview of the clinical background of alectinib, its molecular target, recognized treatment settings, pharmacological activity, clinical response considerations and important safety monitoring requirements.

The information describes the established clinical use of alectinib and should not be interpreted as an individualized treatment recommendation for every product or patient.

Understanding ALK-Positive Non-Small Cell Lung Cancer

Non-small cell lung cancer is the most common broad category of lung cancer. It includes several types of tumors that develop from different cells within lung tissue.

Some NSCLC tumors contain genetic changes that influence how cancer cells grow and survive.

One such alteration involves the anaplastic lymphoma kinase gene.

In certain patients, a rearrangement involving ALK creates an abnormal fusion gene. This gene produces an ALK fusion protein that can remain continuously active.

The abnormal protein activates signaling pathways associated with:

  • Cancer-cell multiplication.
  • Cellular growth and survival.
  • Tumor development.
  • Disease progression.
  • Potential spread to other organs.

An ALK-positive diagnosis means that an appropriate molecular test has identified the relevant ALK alteration.

This finding is clinically important because it may make a patient eligible for treatment with an ALK-targeted medicine.

Alectinib is designed to interfere with this abnormal signaling process.

Molecular Testing Before Treatment

Molecular testing is an important part of selecting patients for alectinib treatment.

A healthcare professional may arrange testing using an appropriate tumor tissue sample or another validated diagnostic specimen.

Testing methods may include:

Immunohistochemistry: This method identifies the presence of specific proteins in tumor tissue. Certain validated tests can be used to assess ALK status.

Fluorescence in situ hybridization: This technique examines genetic material within cells and can identify rearrangements involving the ALK gene.

Next-generation sequencing: This molecular approach can examine multiple genetic alterations and may identify ALK rearrangements alongside other clinically relevant changes.

The appropriate test depends on the clinical situation, specimen quality and applicable diagnostic standards.

Alectinib should not be selected solely because a person has lung cancer. The presence of the relevant molecular alteration and the approved treatment indication must be established.

Mechanism of Action

Alectinib works by inhibiting abnormal ALK tyrosine kinase activity.

Tyrosine kinases are enzymes involved in cellular signaling. They regulate processes such as cell growth, differentiation and survival.

In ALK-positive NSCLC, an abnormal ALK fusion protein can continuously activate signaling pathways that encourage cancer cells to multiply.

Alectinib binds to and inhibits ALK kinase activity, interfering with these signals.

Its pharmacological effects include:

ALK inhibition

Alectinib blocks abnormal ALK signaling, reducing the activity of a molecular pathway that can support cancer-cell growth.

Interference with downstream signaling

ALK activity influences several intracellular pathways involved in cellular proliferation and survival. Inhibiting ALK can reduce signaling through these pathways.

RET inhibition

Alectinib also has activity against RET, another receptor tyrosine kinase. Its primary established clinical role in this context is ALK inhibition.

Central nervous system activity

Alectinib can penetrate the central nervous system. This characteristic is relevant because ALK-positive NSCLC can spread to the brain.

However, central nervous system penetration does not mean that every patient will achieve the same response or that brain metastases will always be controlled.

Approved Clinical Treatment Settings

Alectinib has recognized treatment indications for specified adults with ALK-positive NSCLC.

The exact indications depend on the regulatory authority and country.

1. Adjuvant treatment following surgical resection

In the United States, alectinib is indicated as adjuvant treatment for adults following surgical resection of qualifying ALK-positive NSCLC tumors.

The relevant reference-product indication covers tumors measuring at least 4 cm or involving lymph nodes.

Adjuvant therapy is treatment given after the primary tumor has been surgically removed.

Although surgery may remove the visible cancer, microscopic cancer cells can remain and potentially contribute to recurrence.

The purpose of adjuvant treatment is to reduce the risk of cancer returning.

The U.S. reference-product prescribing information specifies a treatment duration of two years or until recurrence or unacceptable toxicity, whichever occurs first.

2. Metastatic ALK-positive NSCLC

Alectinib is also indicated for adults with metastatic ALK-positive NSCLC under the U.S. reference-product labeling.

Metastatic cancer has spread beyond its original location to other parts of the body.

In this setting, treatment aims to control cancer progression and manage the disease over time.

The duration of therapy is generally determined by continued clinical benefit, disease progression and treatment tolerability.

Treatment should be monitored by an oncology specialist.

Clinical Effectiveness

Alectinib has been evaluated in clinical studies involving patients with ALK-positive NSCLC.

Its clinical development has included studies in advanced disease and in the adjuvant setting after surgery.

Clinical research evaluates several outcomes to understand how well an anticancer medicine performs.

Clinical measureMeaning
Overall response rateProportion of patients whose tumors show a predefined response
Progression-free survivalTime during which the cancer does not worsen according to the study definition
Overall survivalTime from a defined starting point until death from any cause
Disease-free survivalTime after treatment during which cancer does not return or recur
Duration of responseLength of time a documented tumor response continues
Safety outcomesAdverse reactions and complications observed during treatment

The ALINA clinical trial evaluated adjuvant alectinib after surgical resection in patients with ALK-positive NSCLC.

The study demonstrated a significant improvement in disease-free survival compared with platinum-based chemotherapy in the studied population.

The ALEX clinical trial evaluated alectinib against crizotinib in previously untreated advanced ALK-positive NSCLC. It established an important role for alectinib in the management of advanced disease.

Clinical trial results describe outcomes in defined study populations. They cannot predict an individual patient’s response with certainty.

Central Nervous System Considerations

The brain and spinal cord form the central nervous system.

ALK-positive NSCLC can spread to the brain, where treatment selection may be affected by a medicine’s ability to reach the central nervous system.

Alectinib has demonstrated central nervous system activity and has been studied in patients with brain metastases.

This property is clinically important because disease involving the brain can affect neurological function and overall health.

The assessment of brain involvement may include imaging studies and neurological evaluation.

Patients should promptly report new or worsening symptoms such as:

  • Persistent headaches.
  • Seizures.
  • Changes in vision.
  • Difficulty speaking.
  • Weakness.
  • Balance problems.
  • Confusion.
  • Unusual neurological symptoms.

The treating oncologist determines whether additional investigations or treatment adjustments are necessary.

Pharmacokinetic Considerations

Pharmacokinetics describes how a medicine is absorbed, distributed, metabolized and eliminated by the body.

Alectinib is administered orally and is taken with food under the established reference-product prescribing instructions.

The medicine and its active metabolite circulate in the body and contribute to its pharmacological activity.

Alectinib is extensively metabolized, with CYP3A4 playing an important role in its metabolism.

The liver is therefore relevant to its processing, and liver-function monitoring is an important component of treatment safety.

Alectinib also undergoes elimination through fecal and biliary pathways. Its pharmacokinetic properties and potential interactions should be considered when other medicines are prescribed.

Patients should provide their healthcare professional with a complete list of prescription medicines, nonprescription products, vitamins and herbal supplements.

General Reference-Product Dosage

The established U.S. reference-product dose for adults is:

600 mg

Twice daily with food

A total of 1,200 mg per day under the reference-product adult regimen.

Using 150 mg capsules: Four capsules per dose, taken twice daily, provide the reference dose.

This describes the U.S. Alecensa reference-product regimen. It is not an instruction to begin treatment or independently calculate a dose of Alecnib.

The appropriate treatment schedule must be prescribed by an oncology specialist and confirmed against the applicable product information.

Clinical Safety and Monitoring

Alectinib treatment requires regular clinical and laboratory monitoring.

The purpose of monitoring is to identify adverse reactions early and determine whether treatment can continue safely.

Liver function

Alectinib can cause liver toxicity.

Liver enzymes and bilirubin should be assessed before and during treatment.

The U.S. reference-product prescribing information recommends testing every two weeks during the first three months, followed by monthly testing and additional testing when clinically indicated.

Muscle toxicity

Alectinib may cause muscle pain, tenderness and weakness.

Creatine phosphokinase (CPK) testing is recommended every two weeks during the first month and when unexplained muscle symptoms occur.

Heart rate

Alectinib can cause bradycardia, meaning an abnormally slow heart rate.

Heart rate and blood pressure should be assessed as clinically appropriate, especially in patients taking other medicines that may slow the heart rate.

Respiratory symptoms

New or worsening cough, fever or difficulty breathing may indicate interstitial lung disease or pneumonitis.

These symptoms require prompt medical evaluation.

Blood counts

Alectinib can cause hemolytic anemia, which involves the premature destruction of red blood cells.

Blood tests may be necessary when anemia or related symptoms are suspected.

Kidney function

Renal impairment has been reported during treatment. Kidney function should be evaluated according to the patient’s clinical condition.

Lipid levels

Alectinib can cause increased triglyceride levels. Blood lipid testing may be required to identify significant abnormalities.

Important Clinical Safety Warnings

The major safety concerns associated with alectinib include:

Safety concernClinical significance
HepatotoxicityPotential liver injury
Interstitial lung diseaseInflammation of lung tissue
BradycardiaAbnormally slow heart rate
Myalgia and CPK elevationMuscle injury or inflammation
Hemolytic anemiaDestruction of red blood cells
Renal impairmentReduced kidney function
HypertriglyceridemiaIncreased blood triglycerides
PancreatitisInflammation of the pancreas
Embryo-fetal toxicityPotential harm to an unborn baby

Patients should not ignore persistent or severe symptoms during treatment.

Pregnancy and Reproductive Considerations

Alectinib may cause fetal harm.

Pregnancy status and reproductive plans should be discussed with a healthcare professional before treatment.

Patients who may become pregnant should receive advice about effective contraception during treatment and for the recommended period after the final dose.

Patients who can father a child should also discuss the relevant contraception precautions.

Breastfeeding is not recommended during alectinib treatment under the U.S. reference-product prescribing information.

Clinical Limitations

Although alectinib is an established targeted treatment, it does not guarantee a cure or a particular treatment response.

Some tumors may not respond adequately, and cancer can develop resistance to targeted therapy over time.

Treatment selection must consider:

  • ALK molecular status.
  • Cancer stage.
  • Previous treatment.
  • Surgical history.
  • Overall health.
  • Liver and kidney function.
  • Other medicines.
  • Potential adverse reactions.
  • Applicable regulatory indications.

The oncology team determines whether alectinib remains appropriate throughout treatment.

Conclusion

Alecnib 150 mg is identified as a product containing alectinib, an ALK tyrosine kinase inhibitor used in specified patients with ALK-positive NSCLC.

The clinical role of alectinib is based on its ability to inhibit abnormal ALK signaling. It has established treatment uses in qualifying patients following surgical resection and in metastatic ALK-positive disease.

Molecular testing, appropriate patient selection and regular clinical monitoring are essential parts of treatment.

Patients should follow the prescribing instructions provided by their oncology team and seek medical advice when they experience possible adverse reactions. Product-specific information should always be confirmed using appropriate official documentation.